These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 32590021)

  • 1. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
    Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
    Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
    Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
    Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
    Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
    Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status of Immunotherapies for Treating Pancreatic Cancer.
    Wu AA; Jaffee E; Lee V
    Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD
    Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
    Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
    Front Immunol; 2019; 10():1832. PubMed ID: 31440238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
    Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
    World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
    Hegde S; Krisnawan VE; Herzog BH; Zuo C; Breden MA; Knolhoff BL; Hogg GD; Tang JP; Baer JM; Mpoy C; Lee KB; Alexander KA; Rogers BE; Murphy KM; Hawkins WG; Fields RC; DeSelm CJ; Schwarz JK; DeNardo DG
    Cancer Cell; 2020 Mar; 37(3):289-307.e9. PubMed ID: 32183949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.
    Bailey P; Chang DK; Forget MA; Lucas FA; Alvarez HA; Haymaker C; Chattopadhyay C; Kim SH; Ekmekcioglu S; Grimm EA; Biankin AV; Hwu P; Maitra A; Roszik J
    Sci Rep; 2016 Oct; 6():35848. PubMed ID: 27762323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.